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ABSTRACT  
Molecular characterization of radical prostatectomy specimens after systemic 
therapy may identify a gene expression profile for resistance to therapy. This 
study assessed tumor cells from patients with prostate cancer (PC) participating 
in a phase-II neoadjuvant docetaxel (D) and androgen deprivation (AD) trial to 
identify mediators of resistance. Transcriptional level of 93 genes from a D-
resistant PC cell lines microarray study was analyzed by Taqman low-density 
arrays in tumors from patients with high-risk localized PC (36 surgically treated, 
28 with neoadjuvant D+AD). Gene expression was compared between groups 
and correlated with clinical outcome. VIM, AR and P65 were validated by 
immunohistochemistry. CD44 and ZEB1 expression was tested by 
immunofluorescence in cells and tumor samples. Parental and D-resistant 
CRPC cell lines were tested for epithelial-to-mesenchymal transition (EMT) 
markers before and after D-exposure. Reversion of EMT phenotype was 
investigated as a D-resistance reversion strategy. Expression of 63 (67.7%) 
genes differed between groups (P<0.05), including genes related to androgen 
receptor, NFKB transcription factor, and EMT. Increased EMT markers 
expression correlated with radiological relapse. D-resistant cells had increased 
EMT and stem-like cell markers expression. ZEB1 siRNA transfection reverted 
D-resistance and reduced CD44 expression in DU-145R and PC-3R. Before D-
exposure, a selected CD44+ subpopulation of PC-3 cells exhibited EMT 
phenotype and intrinsic D-resistance; ZEB1/CD44+ subpopulations were found 
in tumor cell lines and primary tumors; this correlated with aggressive clinical 
behavior. 
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This study identifies genes potentially related to chemotherapy resistance and 
supports evidence of the EMT role in docetaxel resistance and adverse clinical 
behavior in early PC. 
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Introduction 
Prostate cancer (PC) is the most common malignancy in the Western world and 
the second most common cause of cancer-related mortality in men (1). 
Although most metastatic PC patients respond to androgen deprivation (AD) 
therapy, virtually all of them eventually develop castration-resistant prostate 
cancer (CRPC). In 2004, the combination of docetaxel (D) and prednisone was 
established as the new standard of care for CRPC patients (2). More recently, 
two hormonal agents, abiraterone and enzalutamide, and a new taxane, 
cabazitaxel, have been approved for the treatment of CRPC (3-5). However, 
current therapies are not curative and research is needed to identify predictors 
of benefit and mechanisms of resistance for each agent. 
To date, several factors have been associated with D-resistance, including 
expression of isoforms of ß-tubulin (6), activation of drug efflux pumps (7), 
PTEN loss (8), and expression and/or activation of survival factors (i.e. PI3-
K/Akt and mTOR) (9, 10). Previous work by our group and others has correlated 
the activation of Nuclear Factor Kappa B (NFKB)/interleukin-6 pathways with D-
resistance in CRPC models and in patients (11-13). Other studies support a role 
of Jun/AP-1, SNAIL1, and Notch2/Hedgehog signaling pathways in the 
development of resistance to D or paclitaxel (14, 15). Moreover, it has been 
shown that the inhibition of Androgen receptor (AR) nuclear translocation and 
AR activity may be an important mechanism of taxane action in PC (9). 
In previous work, we identified 243 genes with differential expression in CRPC 
D-sensitive vs D-resistant cell lines (16). In the present study, 73 genes from 
that study together with 20 genes from the literature were tested in tumor 
specimens of high-risk, localized-PC patients included in a clinical trial of 
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neoadjuvant hormone-chemotherapy (17), and compared with nontreated 
specimens with similar clinical characteristics. This approach was based on the 
notion that residual tumor cells in prostatectomy specimens after neoadjuvant 
systemic therapy are likely enriched for resistant tumor cells and their molecular 
characterization may provide important information on mechanisms of 
resistance (18). Our key findings were then tested in two models of D-resistant 
PC cell lines. 
 
PATIENTS AND METHODS 
Patients and samples 
The study included 28 high-risk, localized-PC patients from a previously 
published, multicenter, phase II trial of neoadjuvant D plus AD followed by 
radical prostatectomy (17) and 36 control patients with high-risk PC treated with 
radical prostatectomy without neoadjuvant treatment. Of the 57 participants in 
the clinical trial (17), 29 were not included in this study: 23 patients did not 
consent to participation in the molecular sub-study and insufficient material for 
molecular analysis was available for 6 patients, 3 of whom had a pathological 
complete response (pCR) and 3  had microscopic residual tumor (near pCR) in 
the prostate specimen.  
Inclusion criteria were histologically confirmed adenocarcinoma of the prostate 
with any of the following three risk criteria: [1] clinical stage T3; [2] clinical stage 
T1c or T2 with serum prostate-specific antigen (PSA) >20 ng ml−1 and/or 
Gleason score sum of 8, 9 or 10; or [3] a Gleason sum of 7 with a predominant 
form of 4 (i.e. Gleason score 4+3). Clinical characteristics are shown in Table 1. 
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Treatment consisted of three cycles every 28 days of D 36mg/m2 on days 1, 
8, and 15 concomitant with complete androgen blockade, followed by radical 
prostatectomy. Patients were followed from the time of study inclusion until 
death or last visit. Median follow-up time was 82 months (range, 10-135). PSA 
relapse was defined as two consecutive values of 0.2 ng/mL or greater (19). 
Radiological progression was defined as the progression in soft tissue lesions 
measured by computed tomography or magnetic resonance imaging, or by 
progression to bone (20). 
The study was approved by each participating hospital’s Institutional Ethics 
committee and written informed consent was obtained from all participants. 
Formalin-fixed paraffin-embedded (FFPE) specimens were collected after 
radical prostatectomy. A representative tumor area was selected for each block 
and, according to its size, between 2 and 12 sections were cut, 10 μm thick, and 
used for RNA isolation. Hematoxylin and Eosin (H&E) stained sections from 
tumors and adjacent tissues were prepared to confirm the histological 
diagnosis.  
 
RNA extraction 
Total RNA was isolated from tumor specimens using the RecoverAll Total 
Nucleic Acid Isolation Kit (Life Technologies) according to the manufacturer’s 
protocol. Total RNA was quantified with a spectrophotometer (NanoDrop 
Technologies). 
 
Gene selection 
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In total, 93 target genes that could potentially be related to D-resistance and two 
endogenous control genes (ACTINB and GUSB) were selected for further 
analysis in tumors. A set of 73 target genes was selected for their relative 
expression in docetaxel-resistant cells (DU-145R and PC-3R) vs parental cells 
(DU-145 and PC-3) (16) using DAVID (21) and IPA software 
(http://www.ingenuity.com). Twenty genes highlighted in the literature as 
potential targets of docetaxel resistance were also selected.  
 
Reverse transcription and pre-amplification 
A High-Capacity cDNA Reverse Transcription kit (Life Technologies) was used 
to reverse-transcribe 1 μg of total RNA in a 50 μl reaction volume. cDNA pre-
amplification (PA) was performed by multiplex PCR with the 93 selected genes 
(Supplementary Table S1) and the stem-like cell markers CD24 and CD44, 
following the manufacturer’s instructions for the TaqMan PreAmp Master Mix Kit 
(Life Technologies), except that final volume of the reaction was 25 μl. 
 
Gene expression analysis in FFPE samples 
Pre-amplified cDNA was used for gene expression analysis using 384-Well 
Microfluidic Cards (Life Technologies). Pre-amplified samples were diluted 1:20 
in TE 1X buffer before use. Each card was configured into four identical 96-
gene sets (95 selected genes plus an endogenous control gene, RNA18S, by 
default). The reaction was carried out following manufacturer’s instructions on 
an ABI 7900HT instrument (Life Technologies). Array cards were analyzed with 
RQ Manager Software for manual data analysis.  
on March 25, 2014. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 21, 2014; DOI: 10.1158/1535-7163.MCT-13-0775 
10 
 
Gene expression of CD24 and CD44 markers was studied by amplifying with 
TaqMan Gene Expression Master Mix in a StepOnePlus Real-Time PCR 
system (Life Technologies), according to the manufacturer’s recommendations. 
Relative gene expression values were calculated based on the quantification 
cycle (Cq) values obtained with SDS 2.4 software (Life Technologies). 
Expression values were relative to the GUSB endogenous gene. Samples from 
patients who did not receive neoadjuvant treatment were used for calibration. 
 
Cell culture conditions 
The CRPC cell lines DU-145 and PC-3 were purchased from the American 
Type Culture Collection in October 2009. The D-resistant cell lines DU-145R 
and PC-3R were developed and maintained as previously described (12). No 
further authentication of the cell lines was done by the authors. 
 
Cell proliferation assays 
Cell viability in response to D was assessed by 3-(4,5-dimethylthiazol-2yl-2,5-
diphenyltetrazolium bromide (MTT) assay with the Cell Titer 96 Aqueous 
Proliferation assay kit (Promega, Madison, WI) and by trypan blue exclusion 
method using a Neubauer hemocytometer chamber. 
 
Western Blot Analysis 
Whole-cell extracts were prepared and Western blot performed as described 
previously (22). Antibodies used were Anti-Poly-(ADP-Ribose)-Polymerase 
(PARP). Ab was purchased from Roche (Ref. 11835238001 - Basel, 
Switzerland); β-Catenin (6B3) (CTNNB1) Ab (Ref.9582), CD44 (156-3C11) 
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Mouse mAb (Ref.3570), E-cadherin (CDH1) Ab (Ref.4065), Snail (C15D3) 
Rabbit mAb (Ref.3879), TCF8/ZEB1 (D80D3) Rabbit mAb (Ref.3396), and 
Vimentin (R28) (VIM) Ab (Ref.3932) were purchased from Cell Signaling 
Technologies (Beverly, MA). Monoclonal Anti- α-Tubulin clone B-5-1-2 
(Ref.T5168) was purchased from Sigma-Aldrich (St. Louis, MO). 
 
Real-time qRT-PCR in cell lines 
Total RNA was isolated from cell lines using the RNeasy Micro kit (Qiagen), and 
quantified with a spectrophotometer (Nanodrop Technologies). cDNA was 
generated from 1 μg of total RNA using the High Capacity cDNA Archive Kit 
(Life Technologies), following manufacturer’s instructions. Real-time qRT-PCR 
was carried out in a StepOnePlus Real-Time PCR system (Life Technologies) 
according to the manufacturer’s recommendations. Data were acquired using 
SDS Software 1.4. Amplification reactions were performed in duplicate. 
Expression values were relative to the ACTB endogenous gene. Target genes 
were amplified using commercial primers and probes (Life Technologies) 
(Supplementary Table S1). 
 
Immunohistochemistry (IHC) 
Tissue sections were deparaffinized in xylene and rehydrated in graded 
alcohols. For AR and VIM staining, the sections were placed in a 97ºC solution 
of 0.01 mol/L EDTA (pH 9.0) for antigen retrieval. Primary mouse mononuclear 
antibody for AR (DAKO, Agilent Technologies, US) was applied for 20 minutes 
at room temperature at dilution 1:150. FLEX Monoclonal Mouse Anti-VIM, Clon 
V9 (DAKO) was used for VIM staining. Detection was accomplished with the 
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DAKO Envision System followed by diaminobenzidine enhancement. For P65, 
the sections were placed in a 97ºC solution of 0.01 mol/L sodium citrate (pH 
6.0) for antigen retrieval. Then, samples were incubated with a rabbit polyclonal 
antibody (Santa Cruz biotechnology, Inc, US) at dilution 1:400. Detection was 
performed with Bond Polymer Refine Detection (DAKO, Agilent Technologies, 
US) for the automated Bond system. 
AR and P65 were evaluated throughout the semiquantitative method 
histological score (HSCORE), which measures both the intensity and proportion 
of staining. The HSCORE for each sample was calculated by multiplying the 
percentage of stained tumor cells by the intensity (0: non-stained; 1: weak; 2: 
moderate; 3: strong). VIM was evaluated in the same way but scoring the 
percentage of staining on a scale of 0 to 4 (0: 0; 1: <1%; 2: 1-9%; 3: 10-50%; 4: 
>50%). Nuclear and cytoplasmatic stains were scored separately for AR and 
P65 proteins. The assessment of all samples was done by a senior pathologist 
(P.L.-F) who was blinded to all clinical information. 
 
Immunofluorescence staining in cell lines and tumor samples 
Cell pellets were collected in a 1% agarose solution, fixed in 4% PBS-buffered 
formaldehyde, and then formalin-fixed and paraffin-embedded. Sections of 5 μm 
were analyzed with a multiplex immunofluorescent assay. They were stained 
with Hematoxylin and Eosin (H&E) for histopathologic assessment and stained 
using immunofluorescence (IF) with Alexa fluorochrome-labeled antibodies. 
Briefly, both control and resistant PC cell lines were evaluated with a series of 
simplex and duplex IF assays to quantify the level of selected antibody-antigen 
complexes from specific regions of interest (ROI). 
on March 25, 2014. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 21, 2014; DOI: 10.1158/1535-7163.MCT-13-0775 
13 
 
The FFPE prostate tissue sections also were assessed by IF using a single 
multiplex assay with 2 differentially labeled antibodies (ZEB1 and CD44). For all 
specimens the H&E images were used to guide and register IF image capture 
with a maximum of 4 ROIs per cell pellet and 6 per tissue section. Alexa 
fluorochrome dyes were Vimentin (Ref. MO725, Dako), CD44 (Ref.: 156-3C11, 
Cell Signaling Technology), ZEB1 (Ref.: sc-25388, Santa Cruz). The ROI were 
acquired from the cells and tumor tissue sections, blinded to outcome, with a 
CRI Nuance imaging system, and then analyzed with fluorescent image 
analysis software to derive quantitative features from cellular/tissue 
compartments. Quantitative assessment was performed using a pixel-area 
function, normalized to the ROI under investigation. 
 
Small interfering RNA transfection  
Dharmacon SMART pool control and ZEB1 siRNA were used with lipofectamine 
according to the manufacturer’s protocol (Thermo Scientific) to inhibit ZEB1 in 
DU-145/R cells. Commercial Silencer Select siRNA of ZEB1 (s229971; Life 
Technologies) was transfected to PC-3/R cell lines. Cells were incubated with 
the siRNA complex for 24 hours, treated with D, then harvested to study protein 
expression changes of ZEB1 and CDH1 by Western blot. Apoptosis was 
studied at 24 and 48 hours by PARP analysis (Western blot), and cell viability 
was measured by MTT at 72 hours as described before. 
 
Fluorescence-activated cell sorting (FACS) 
For flow cytometry, cells were dissociated with Accutase (Invitrogen) and 
washed twice in a serum-free medium. Cells were stained live in the staining 
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solution containing BSA and FITC-conjugated monoclonal anti-CD44 (15 min at 
4 ºC). A minimum of 500,000 viable cells per sample were analyzed on a 
cytometer. For FACS, 2-5 x 107 cells were similarly stained for CD44 and used 
to sort out CD44+ and CD44- cells. For the positive population, only the top 10% 
mostly brightly stained cells were selected. The CD44+ cells selected were 
cultured as an individual clone in 96-well plates and expanded. 
 
Statistical Analysis 
TLDAs gene expression data was evaluated by Wilcoxon rank-sum test and 
receiver operating characteristic analysis. Time to PSA progression and 
radiological progression were calculated from the time of prostate cancer 
diagnosis until PSA or radiological progression, respectively. The log-rank test 
was used in univariate survival analyses. Multivariate analysis of gene 
expression was evaluated by Cox proportional hazards regression including 
stage, Gleason, PSA and neoadjuvant treatment as clinical covariates; 
backward stepwise likelihood was used for selection. Real-time qRT-PCR 
experimental data was expressed as mean + SEM and was analyzed by 
Student t test. All the statistical tests were conducted at the two-sided 0.05 level 
of significance. 
 
RESULTS 
Differential gene expression between treated and nontreated tumors 
Among the 93 genes analyzed (Supplementary Table S1), we observed 
differential expression (P < 0.05) in 63 (67.7%) genes (Table 2); 53 genes were 
overexpressed and 10 under-expressed in tumor specimens from patients 
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treated with neoadjuvant D plus AD. Genes of the NFKB pathway (such as 
NFKB1, REL, RELA), AR and epithelial-to-mesenchymal transition (EMT)-
related genes (such as ZEB1, VIM, CDH2, TGFBR3) were overexpressed in 
treated tumors. Among the down-regulated genes in treated tumors, were the 
metastasis suppressor gene NDRG1 (23) and the adhesion molecule EPCAM, 
a regulator of the alternative splicing of CD44 (ESRP1) (24) and ST14 (a 
negative regulator of the EMT mediator ZEB1) (25)(Table 2, Fig. 1A).  
 
Gene expression and clinical outcome  
We tested the possible prognostic impact of the 93 genes studied by TLDAs 
(Supplementary Table S1). Individually, the expression of several genes was 
related to time-to-PSA and/or clinical relapse (Table 2). Time to radiological 
progression and PSA progression curves are shown in Figure 1B, 1C and 
Supplementary Figures S1 and S2. Of note, the overexpression of AR, and the 
EMT-related genes TGFBR3, ZEB1, and VIM was correlated with a shorter time 
of radiological progression (Fig. 1B). 
We then performed a multivariate analysis including the genes with individual 
prognostic value, clinical prognostic factors (PSA, Gleason, and clinical stage), 
and neo-adjuvant treatment. Results are shown in table 2A and 2B. In the 
multivariate analysis, the reduced expression of CLDN7 was an adverse 
independent prognostic factor for clinical relapse. Loss of CLDN7 has been 
correlated with adverse prognostic variables in PC and with EMT (26). Of note, 
the low expression of CDH1 was an independent prognostic factor for time to 
PSA relapse.  
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We also analyzed the prognostic impact of the stem-like cell markers CD24 and 
CD44, which were underexpressed and overexpressed, respectively, in treated 
tumors (FC CD24: 0.59, P=0.07; FC CD44: 1.63, P<0.000) (Supplementary 
table 1 and supplementary figure 1 and 2). Of note, low expression of CD24 
was correlated with shorter time of biochemical progression (Fig. 1C). 
 
Immunohistochemistry in treated vs nontreated tumors 
We explored the expression of VIM and both cytoplasmatic and nuclear P65 
and AR in tumor samples from neoadjuvant-treated and non-treated patients. 
Staining of cytoplasmatic P65 was significatively higher in the treated vs non-
treated patients (IHC score 181.9 vs 148.3, respectively) (Fig. 1D,F). Moreover, 
nuclear P65 was significantly related to worse clinical relapse (Fig. 1E). 
Vimentin expression was nonsignificantly higher in treated tumors (IHC score 2 
vs 1, respectively) (Fig. 1D). No differences were found in the expression of 
nuclear AR; however, cytoplasmatic AR expression was significantly higher in 
the treated tumors (IHC score 102.5 vs 14.5) and correlated with radiological 
progression survival (Fig. 1D,E,F). 
D-resistant prostate cancer cells express EMT and stem-like cell markers 
Based on the results described above, we studied the link between EMT and D-
resistance in four PC cell lines models (parental DU-145 and PC-3R cells, and 
their docetaxel-resistant partners DU-145R and PC-3R, respectively). As shown 
in Figure 2A and 2B, the D-resistant cells phenotype was consistent with EMT, 
i.e., decreased expression of epithelial markers (CDH1 and CTNNB1) and 
increased expression of mesenchymal markers (VIM and ZEB1) at the protein 
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level. Consistent results were found at mRNA level, except for CTNNB1 (data 
not shown).  
Recent studies have shown that cells with EMT phenotype share characteristics 
of stem-like cancer cells (14, 27). For that reason we tested the expression of 
stem-like cell markers and showed that D-resistant cells, both DU-145R and 
PC-3R, exhibit transcriptional features of cancer-stem cells, such as increased 
expression of CD44 and the loss of CD24 (Fig. 2C).  
Moreover, in cell lines we detected by IF analysis a subset of cells co-
expressing CD44 and ZEB1. Scattered cells with these features were 
detectable in the parental cell lines; however, this population was highly 
enriched in the resistant cells (Fig. 2D). By FACS, we then isolated from the 
parental PC-3 cells a subpopulation of cells with high expression of CD44. We 
selected a derived-CD44+/PC-3 clone that showed an increased expression of 
VIM and ZEB1 and decreased CDH1 expression (Fig. 2E). This clone from the 
parental cells was significantly more resistant to D than the parental cell line, 
PC-3 (Fig. 2F). 
Dose-response experiments in both parental and resistant cells showed that D 
exposure significantly increased the expression of VIM in PC-3 and PC-3R 
cells, of ZEB1 in PC-3 cells, and of SNAI1 in DU-145, PC-3 and PC-3R cells. 
TWIST1 expression increased in all cell lines after D treatment. In contrast, no 
significant differences were observed in the expression of SNAI2 and CDH1 
with D exposure (Fig. 3A). Regarding stem-like cell markers, inconsistent 
results were obtained for CD24 expression after D exposure because CD24 
expression increased in PC-3 cells but decrease in DU-145 cells. In contrast, 
CD44 significantly increased in PC-3 cells with D treatment (Fig. 3B).  
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EMT mediates docetaxel resistance in prostate cancer cells 
To test whether inhibition of EMT could revert D resistance, we down-
modulated the expression of ZEB1, a key inducer of EMT. siRNA ZEB1 
transfected DU-145R and PC-3R cells had an increased expression of CDH1 
(Fig. 4A) and CD44 (Fig. 4B), confirming the link between EMT and stem-like 
cell phenotype. Moreover, si-RNA ZEB1 transfected cells showed significantly 
increased sensitivity to D compared to control cells (P < 0.05) (Fig. 4B and 4C). 
The magnitude of the reversion of chemoresistance was more pronounced in 
DU-145R and PC-3R cells than in the parental cells. D-induced apoptosis was 
more pronounced in the ZEB1-siRNA transfected cells (Fig. 4B). 
 
ZEB1/CD44 expression in tumor samples 
Based on preclinical findings, we decided to investigate whether CD44+/ZEB1+ 
cells were present in primary PC specimens. Twenty-two FFPE tumors from 
high-risk PC patients treated with D and androgen suppression and 15 control 
patients with sufficient remaining material were available for IF studies. All 
samples were positive for CD44 staining but only 7 of 15 controls (46.7%) and 7 
of 22 treated patients (31.8%) had a ZEB1 signal. Overall, there were no 
differences between the control and treated groups in the expression of ZEB1 
(0.0059 vs 0.013 mean intensity, respectively) or CD44 (1.27 vs 1.01 mean 
intensity, respectively). Tumor cells that co-expressed ZEB1 and CD44+ were 
observed in 3 (13.6%) of the 22 patients in the neoadjuvant group. However, 
none of the control patients presented with co-expression of both markers (Fig. 
4D). Notably, ZEB1/CD44 co-expression was associated with aggressive 
clinical behavior: at the time of outcome analysis, all patients had relapsed, 2 
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had developed liver metastasis, and 1 had died due to disease progression 
(Fig. 4E). 
 
DISCUSSION 
In this study we confirm that some of the molecular alterations associated with 
D-resistance in a previously described in vitro model of CRPC cell lines are 
present in residual cells of prostatectomy specimens treated with neoadjuvant D 
plus AD. Our findings may be especially relevant in clinical practice because 
most patients receive AD prior and concomitantly to the administration of D. The 
observed deregulated pathways may translate common mechanisms of 
resistance to both therapies. 
Different neoadjuvant studies have been designed to identify pathways involved 
in resistance to AD or chemotherapy in PC. In one study of neoadjuvant AD, the 
authors observed that many androgen-responsive genes, including AR and 
PSA, were not suppressed; this suggests that suboptimal suppression of 
tumoral androgen activity may lead to adaptive cellular changes to allow PC 
cells survival in a low-androgen environment (28). Another group analyzed 
prostate tumors removed by radical prostatectomy after 3 months of AD. Gene 
expression analysis revealed that PSA and other androgen-responsive genes 
were overexpressed in tumors from patients who relapsed (29). Our data are in 
concordance with these reports. We observed that the expression of AR and 
several AR-regulated genes (i.e, ZEB1, IL6, TGFBR3, KLF9) increased in 
treated tumors, even though serum PSA levels decreased under therapy in 
most cases, as we previously reported (17). Moreover, high levels of AR 
correlated with high risk of clinical-relapse. These data suggest that persistence 
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of AR signalling may be related to treatment resistance and/or to eventual 
disease progression. 
We observed no differences in nuclear staining between treated and non-
treated samples. However, cytoplasmatic expression was significantly higher in 
residual tumor cells after AD and D exposure. Prior reports have shown that 
taxanes inhibit AR nuclear translocation and that patients treated with taxanes 
may have lower nuclear expression than treatment-naïve patients (30). This 
was not observed in our study, likely because our patients were treated with 
combined therapy. Prior studies have shown that androgen deprivation induced 
full-length androgen receptor protein levels in CRPC cells, but decreased its 
nuclear localization (31). 
Other studies have used a similar approach in patients treated with neoadjuvant 
chemotherapy alone (32, 33). One group performed microarray analysis of 
tumor specimens from 31 patients treated with D plus mitoxantrone (33). The 
comparison of pre- and post-treatment samples showed increased expression 
of cytokines regulated by the NFKB pathway. These data are in concordance 
with our results showing an increased expression in treated tumors of NFKB 
subunits and NFKB regulated cytokines, such as IL6, adding support to a body 
of evidence on the involvement of this pathway in resistance to chemotherapy in 
PC (11). On the other hand, NFKB activation may induce EMT in PC (34). 
Although our study did not investigate the potential causal relationship between 
NFKB activation and EMT, this last phenomenon was found to be highly 
relevant in resistance to therapy. Moreover, increased nuclear NFKB (P65 
staining) correlated with a shorter time to clinical relapse, confirming the 
prognostic value of this pathway activation in PC (22). 
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In the present study we analyze the transcriptional profile of residual tumor cells 
after combined neoadjuvant AD and D treatment. Since macrodissected tumor 
tissues were used for gene expression studies, our results may translate 
expression patterns from both tumor and surrounding non-tumor cells. 
However, a prior study using the macrodissection strategy reported only minor 
interference of non-tumor cells with the overall gene expression profile (35). 
Moreover, we considered stroma and benign cells contamination to be 
homogeneous in both the treated and non-treated patient groups. Among the 93 
genes analyzed, we observed differential expression between treated and 
nontreated tumors in 63 (67.7 %) genes. Of note, the over expression of the 
EMT genes correlated with a shorter time to clinical relapse.  
In the EMT process, cells lose epithelial characteristics and gain mesenchymal 
properties to increase motility and invasion, allowing tumor cells to acquire the 
capacity to infiltrate surrounding tissues and to metastasize in distant sites.  
EMT is typically characterized by the loss of epithelial (i.e. CDH1) and the gain 
of mesenchymal (i.e. VIM, CDH2) markers expression (36). Several reports 
suggest that AR activation, as well as androgen deprivation therapy, may 
induce changes characteristic of EMT that may be involved in PC progression 
(37-39). The expression of the transcription factor ZEB1 may be induced by 
dihydrotestosterone and is mediated by two androgen-response elements (40). 
Recently, Sun et al. showed that androgen deprivation causes EMT in animal 
models and in tumor samples of patients treated with hormone therapy (41).  
Moreover, the presence of AR-truncated isoforms, which are increased in the 
castration-resistant progression, regulate the expression of EMT (42). 
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On the other hand, there are molecular similarities between cancer stem-like 
cells and EMT-phenotypic cells. Moreover, cells with an EMT phenotype 
induced by different factors are rich sources for stem-like cancer cells (14, 27). 
We observed in the DU-145 in vitro model that D-resistant cells expressed high 
levels of the stem-cell marker CD44 and decreased levels of CD24. Moreover, 
D treatment increased CD44 expression in tumor cells. Likewise, RT-PCR 
results in tumor samples showed an increased expression of CD44 and a 
decreased expression of CD24 in tumors treated with neoadjuvant AD plus D. 
Our results are in accordance with those of Puhr et al, who detected an 
increased CD24low-CD44high cell population in D-resistant PC models (43). 
Similarly, Li et al detected CD24low-CD44high breast cancer cells that were 
resistant to neoadjuvant chemotherapy (44). In a preclinical study, CD44 and 
CD147 enhanced metastatic capacity and chemoresistance of PC cells, 
potentially mediated by activation of the PI3K and MAPK pathways (45). 
In the present work we identified a population of PC cells exhibiting an EMT 
phenotype that are primarily resistant to D. The presence of an intrinsic 
resistant cell population was supported by the isolation of D-resistant clonal 
cells in the parental cell line PC-3, before D exposure, with a high expression of 
CD44 and EMT markers and the loss of CDH1. ZEB1+/CD44+ cells were 
identified at a very low frequency in the two parental cell lines, DU-145 and 
PC3, before D exposure but their frequency massively increased in D-resistant 
cells. Similarly, a small percentage of ZEB1+/CD44+ cells were also observed in 
primary high-risk localized PC tumors. ZEB1+/CD44+ cells were present only in 
tumors that had previously received neoadjuvant AD plus D (13.6%). Both in 
vitro and tumor sample findings support the presence of primary resistant cells 
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harboring EMT/stem cell-like characteristics and suggest that the exposure to D 
may eliminate sensitive cells resulting, however, in the selective out-growth of 
this resistant cell population.  
In our model, D also induced EMT changes in the parental and resistant cell 
lines. Based on our findings, both mechanisms, the existence of a primary 
resistant cell with an EMT phenotype and the induction of EMT changes 
induced by D, are possible. In recent work on D-resistant PC-3 and DU-145 
derived cell lines, the authors reported that D-resistant cells underwent an EMT 
transition associated with a reduction of microRNA (miR)-200c and miR-205, 
which regulate the epithelial phenotype. Their study also showed reduced 
CDH1 expression in tumors after neoadjuvant chemotherapy (43). Another 
study showed that paclitaxel-DU-145 resistant cells have greater ZEB1, VIM, 
and SNAI1 expression (46).  
We tested whether EMT played a causal role in D chemoresistance by 
interfering with the expression of the transcription factor ZEB1, a key mediator 
of EMT, in PC cell lines. We observed that ZEB1 genetic down-modulation 
restored CDH1 but suppressed CD44 expression, which was consistent with a 
reversion of EMT and stem-like cell features. We also observed that ZEB1 
inhibition caused PC cell mortality independently of D. This effect was 
previously described and is consistent with the known role of ZEB1 in cell 
proliferation related, which is related to the expression of cell cycle inhibitory 
cyclin-dependent kinase inhibitors (47). Furthermore, ZEB1 inhibition restored 
sensitivity to D, supporting a mechanistic role of EMT and stem-like cell 
phenotype in resistance to therapy. In a previous study of an adenocarcinoma 
lung cancer model, inhibition of ZEB1 significantly enhanced the 
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chemosensitivity of D-resistant cells in vitro, and in vivo the ectopic expression 
of ZEB1 increased chemoresistance (48). 
Several reports have provided evidence that EMT is critical for invasion and 
migration and is involved in tumor recurrence, which is believed to be tightly 
linked to cancer stem cells. CD44 and VIM expression in primary tumors has 
been correlated with adverse prognosis (34, 49). Notably, the few patients in 
our series with ZEB1+/CD44+ tumor cells in primary tumors showed extremely 
aggressive clinical behavior.  
In summary, we observed a differential expression of NFKB, AR, EMT and 
stem-like cell markers between treated and not-treated tumors. Moreover, they 
were related to a higher risk of PSA and/or clinical relapse. Since the 
neoadjuvant population may be of higher risk than the surgical patients, we 
cannot exclude the possibility that the expression of these markers is more 
related to the characteristics of the disease than to the therapy. However, none 
of the clinical factors (PSA, Gleason, clinical stage, or the presence of prior 
neoadjuvant therapy) correlated with clinical outcome in the univariate or 
multivariate analysis in our series.  
Overall, our findings support a role of EMT in resistance to PC therapy and 
progression. Our clinical data were generated in the neoadjuvant setting and 
cannot be extrapolated to CRPC patients. However, both in vitro and clinical 
results support the investigation of the role of EMT in resistance to 
chemotherapy in CRPC. Moreover, novel strategies to revert or prevent EMT 
are warranted to improve the outcome of CRPC or to increase the probabilities 
of cure for high-risk PC patients.  
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TABLES  
Table 1: Clinical characteristics of patients. N/A: Not available; 1Missing 
information; 2In some cases Gleason score could not be assessed because of 
tissue changes related to neoadjuvant treatment. 
 
 All 
Neoadjuvant 
treatment Control 
Total number 64 28 36 
Median age (years) 64 (range, 46 - 74) 64 (range, 48 - 70) 64.5 (range, 46 - 74) 
Clinical Stage 
T1 19 (29.7%) 4 (14.3%) 15 (41.7%) 
T2 33 (51.6%) 14 (50%) 18 (50%) 
T3 12 (18.8%) 10 (35.7%) 3 (8.3%) 
Pathological Stage 
T0 1 (1.6%) 1 (3.6%) 0 
T1 1 (1.6%) 1 (3.6%) 0 
T2 26 (40.6%) 13 (46.4%) 13 (36.1%) 
T3 36 (56.3%) 13 (46.4%) 23 (63.9%) 
Gleason score (Biopsy) 
≤ 6 10 (15.6%) 2 (7.1%) 8 (22.2%) 
7 (3+4) 22  (34.4%) 7 (25%) 15 (41.7%) 
7 (4+3) 16 (25%) 8 (28.6%) 8 (22.2%) 
7(N/A1) - - 1 (2.8%) 
8 11 (17.2%) 8 (28.6%) 3 (8.3%) 
9 4 (6.3%) 3 (10.7%) 1 (2.8%) 
Gleason score 
(Prostatectomy) 
N/A2  18 (28.3%) 18 (64.3%) 0 
≤ 6 7 (15.2%) 7 (25%) 0 
7 (3+4) 13 (20.3%) 1 (3.6%) 12 (33.3%) 
7 (4+3) 17 (26.6%) - 17 (47.2%) 
8 2 (4.3%) 0 2 (5.6%) 
9 7 (15.2%) 2 (7.1%) 5 (13.9%) 
Median PSA (ng/ml) 8.7 (range, 2.01 - 41) 12.2 (range, 4.7 - 41) 8.2 (range, 2.01 - 19.2) 
PSA (ng/ml) 
< 20 56 (87.5) 20 (71.4%) 36 (100%) 
> 20 8 (12.5%) 8 (28.6%) 0 (0%) 
Postoperative radiotherapy 
No 35 (58.3%) 13 (54.2%) 22 (61.1%) 
Yes 24 (40%) 10 (41.7%) 14 (38.9%) 
N/A1 1 (1.7%) 1 (4.2%) 0 (0%) 
Biochemical relapse 
No 30 (46.9%) 11 (39.3%) 19 (52.8%) 
Yes 34 (53.1%) 17 (60.7%) 17 (47.2%) 
Median biochemical relapse 
free survival (months)  
31.7 (range, 4 - 81) 29.3 (range 4 - 59) 34.1 (range, 8 - 81) 
Clinical relapse 
No 58 (90.6%) 22 (78.6%) 36 (100%) 
Yes 6 (9.4%) 6 (21.4%) 0 (0%) 
Median clinical relapse free 
survival (months)  
51.2 (range, 31 - 84) 51.2 (range, 31 - 84) - 
Follow-up (months) 82 (range, 10 - 135) 91 (range, 81 - 96) 69 (range, 10 - 135) 
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Table 2: Multivariate analysis of gene expression and patient outcomes. bPFS: biochemical progression-free survival; rPFS: radiological 
progression-free survival; False discovery rate for differentially expressed genes was < 0.074 in all cases; FC: Fold change; aSignificant Cox 
regression analysis; HR: Hazard ratio; 95%CI: 95% confidence interval. P < 0.05. 
  Gene FC Progression Multivariatea HR; CI95% Gene FC Progression Multivariatea HR; CI95% Gene FC Progression Multivariatea HR; CI95% 
D
i
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l
l
y
 
e
x
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e
d
 
g
e
n
e
s
 
TGFBR3 4.48 rPFS ABCB1 2.46 - NFKB1 1.76 bPFS 
SERPINB5 4.43 - CDH2 2.45 - AR 1.73 rPFS 
CST6 4.19 - LTB 2.40 - PTPRM 1.71 - 
CLDN11 3.69 rPFS. bPFS 3.056 TIMP2 2.38 rPFS  REL 1.68 bPFS  (1.169-7.988) rPFS 
GPR87 3.65 bPFS ID2 2.38 - KLF9 1.50 rPFS 
AREG 3.42 - EFEMP1 2.35 rPFS BRCA1 1.47 - 
SCD5 3.32 rPFS  FRMD3 2.32 -  SMAD4 1.36 bPFS 
0.163 
(0.058-0.457) 
TMEM45A 3.30 rPFS HTRA1 2.31 - FRMD4A 1.31 - 
MAP7D3 3.23 -  LAMC2 2.22 bPFS 
0.131 GSPT2 1.29 -  (0.027-0.634) 
VIM 3.23 rPFS  SLC1A3 2.17 rPFS. bPFS 
2.555 FN1 1.20 -  (1.088-5.999) rPFS 
BCL2A1 3.09 -  ZEB1 2.16 rPFS  GOSR2 1.16 -  
PLSCR4 3.01 rPFS IFI16 2.15 - NDRG1 -1.27 - 
SCARA3 3.01 -  EGFR 2.11 -  BTBD11 -1.41 bPFS 
0.321 
(0.143-0.720) 
ITGB2 2.92 - SAMD9 2.09 - CCNB1 -1.41 - 
SAMD12 2.80 rPFS. bPFS FBN1 2.03 - ESRP1 -1.46 - 
S100A4 2.80 rPFS FAS 1.91 - FBP1 -1.53 - 
G0S2 2.79 - TACSTD2 1.83 - EPCAM -1.73 - 
SLCO4A1 2.75 rPFS RELA 1.81 rPFS AIM1 -1.98 - 
SNAI1 2.71 - 
 
TXNIP 1.77 rPFS  FLJ27352 -2.09 rPFS. bPFS 
0.257 
(0.113-0.584) rPFS 
IL6 2.64 rPFS 0.112 KLHL24 1.77 rPFS  ST14 -2.19 rPFS  (0.015-0.856) rPFS 
LOC401093 2.49 -   EML1 1.76 rPFS   C1orf116 -6.08 rPFS   
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CBLB ns bPFS 0.315 CSCR7 ns bPFS 0.241 RAB40B ns bPFS 0.314 (0.143-0.695) (0.077-0.755) (0.134-0.739) 
CCPG1 ns bPFS 0.263 EPS8L1 ns bPFS  SCEL ns rPFS  (0.118-0.585) 
CDH1 ns bPFS 0.446 IGF1R ns bPFS 
 
SERPINA1 ns rPFS 0.032 (0.217-0.917) (0.002-0.632) 
CDK19 ns rPFS  LOC401093 ns rPFS  TP53INPL ns rPFS  
CLDN7 ns rPFS 0.054 MALAT1 ns rPFS. bPFS 0.361 
    (0.004-0.699) (0.141-0.921) rPFS 
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FIGURE LEGENDS 
Figure 1: Gene expression profile and related outcome of patients treated with 
neoadjuvancy vs nontreated patients. A. Heatmap of differentially expressed 
genes in tumor samples from neoadjuvant-treated patients, compared to those 
without treatment (P < 0.05). Rows represent genes and columns represent 
samples. Red pixels: upregulated genes; Green pixels: downregulated genes; 
B. Radiological progression-free survival analysis of patients according to gene 
expression of AR and the EMT-related markers TGFBR3, ZEB1 and VIM. High 
and low expression was established according to ROC curve analysis. Log-rank 
test was used to assess the statistical difference between the two groups (P < 
0.05); C. Kaplan-Meier curve representing biochemical progression-free survival 
analysis of patients according to gene expression of the stem-like cell marker 
CD24. High and low expression was established according to ROC curve 
analysis. Log-rank test was used to assess the statistical difference between 
the two groups (P < 0.05); D. Immunohistochemistry (IHC) of VIM and nuclear 
and cytoplasmatic P65 and AR. Box plot represents IHC scores for each 
protein. *P < 0.05. E. Kaplan-Meier graphs representing radiological 
progression-free survival analysis of patients according to cytoplasmatic AR and 
P65 nuclear staining by IHC. Log-rank test was used to assess the statistical 
difference between the two groups (P < 0.05); F. Images show representative 
immunohistochemical staining for nuclear P65 and cytoplasmatic AR protein in 
prostate cancer tumors. Magnifications illustrate high and low staining of cells.   
 
Figure 2: EMT and stem cell markers in parental and D-resistant cell lines. A. 
Western blot in DU-145, DU-145R, PC-3 and PC-3R cell lines of epithelial 
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markers (CDH1, CTNNB1) and mesenchymal markers (VIM, ZEB1). Tubulin 
was used as a load control; B. Gene expression of EMT markers by qRT-PCR 
in DU-145, DU-145R, PC-3, and PC-3R cell lines. Data shown is the mean + 
SEM of cell lines from triplicate experiments (*P < 0.05); C. Gene expression of 
stem-cell markers by qRT-PCR in DU-145, DU-145R, PC-3, and PC-3R cell 
lines. Data shown is the mean + SEM of cell lines from triplicate experiments 
(*P < 0.05); D. Confocal immunofluorescence of CD44 (red) and ZEB1 (green) 
in DU-145, DU-145R, PC-3, and PC-3R lines. Colocalization of ZEB1 and CD44 
results are in yellow. Nuclei are stained with DAPI (blue); E. Western blot in 
parental PC-3 and a subpopulation of parental PC-3 cells (clone) sorted by 
CD44 marker. Tubulin was used as a load control; F. Viability assay of PC-3 
and PC-3 clone under docetaxel treatment performed by Tripan Blue method 
(*P < 0.05).   
 
Figure 3: Effect of docetaxel exposure on EMT and stem-like gene expression 
markers in prostate cancer cell lines. A. EMT markers gene expression in a 
docetaxel dose-response manner; B. Stem-like cell markers gene expression in 
a docetaxel dose-response manner; Geometrical symbols represent significant 
differences in the corresponding cell line; data from DU-145 0nM was 
considered the reference for all the other measures (ie FC=1). 
 
Figure 4: Inhibition of ZEB1 in parental and docetaxel-resistant cell lines. 
ZEB1-CD44 staining in prostate tumor specimens. A. Western blot of CDH1 
and ZEB1 in the four cell lines (DU-145, DU-145R, PC-3 and PC-3R) when 
ZEB1 was inhibited by siRNA. B. Western blot of CD44 and PARP in the four 
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cell lines (DU-145, DU-145R, PC-3 and PC-3R transfected cells) treated with 
docetaxel; the band of CD44 in PC-3 and PC-3R corresponds to the variant 
CD44v6; C. MTT of ZEB1-siRNA transfected cells. Data represents mean + 
SEM of triplicate experiments. *P < 0.05; D. CD44 and ZEB1 
immunofluorescence image of a prostate tumor biopsy from a patient treated 
with neoadjuvant docetaxel and androgen deprivation; E. Kaplan-Meier 
according to immunofluorescence intensities of CD44–ZEB1 colocalization and 
clinical/biochemical relapse of patients treated with neoadjuvant docetaxel and 
controls without neoadjuvant treatment.  
C: non-trasnfected cells; Lipo: control lipofectamine; si: siRNA-ZEB1. 
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